Our findings suggest the clinical significance of SUSD2 as a biomarker for EGFR+ HER2+ breast cancer and highlight the use of STAT3-specific inhibitors for treating EGFR+ HER2+ breast cancer expressing SUSD2. Here, ERBB2 is linked to breast cancer.